1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Anti-Infective Drugs Market
2.2. Global Anti-Infective Drugs Market, By Drug Class, 2023 (US$ Million)
2.3. Global Anti-Infective Drugs Market, By Route of Administration, 2023 (US$ Million)
2.4. Global Anti-Infective Drugs Market, By Indication, 2023 (US$ Million)
2.5. Global Anti-Infective Drugs Market, By Distribution Channel, 2023 (US$ Million)
2.6. Global Anti-Infective Drugs Market, By Geography, 2023 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2023

3. Anti-Infective Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Anti-Infective Drugs Market Vendors
3.2. Strategies Adopted by Anti-Infective Drugs Market Vendors
3.3. Key Industry Strategies
4. Anti-Infective Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Anti-Infective Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Antibacterials
5.3.1.1. B-lactams
5.3.1.2. Quinolones
5.3.1.3. Macrolides
5.3.1.4. Tetracycline
5.3.1.5. Aminoglycoside
5.3.1.6. Others (Phenicols, Sulfonamides, etc.)
5.3.2. Antivirals
5.3.2.1. Miscellaneous Antivirals
5.3.2.2. Adamantane Antivirals
5.3.2.3. Antiviral Boosters
5.3.2.4. Others (Antiviral Combinations, Antiviral Interferons, etc.)
5.3.3. Antifungals
5.3.3.1. Azoles
5.3.3.2. Echinocandins
5.3.3.3. Polyenes
5.3.3.4. Others
5.3.4. Others (Antiparasitics, Anthelmintics, etc.)

6. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Others (Topical, etc.)

7. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2023 Versus 2032
7.3. Market Segmentation
7.3.1. Pneumonia
7.3.2. Sepsis
7.3.3. Tuberculosis
7.3.4. Influenza
7.3.5. HIV Infection
7.3.6. Hepatitis Virus Infection
7.3.7. Respiratory Virus Infection
7.3.8. Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.)

8. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2023 Versus 2032
8.3. Market Segmentation
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies


9. North America Anti-Infective Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
9.4. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
9.5. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
9.6.Anti-Infective Drugs Market: By Region, 2022-2032, USD (Million)
9.6.1.North America
9.6.1.1. U.S.
9.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
9.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
9.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
9.6.1.2. Canada
9.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
9.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
9.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
9.6.1.3. Rest of North America
9.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
9.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
9.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)

10. UK and European Union Anti-Infective Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.4. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.5. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.Anti-Infective Drugs Market: By Region, 2022-2032, USD (Million)
10.6.1.UK and European Union
10.6.1.1. UK
10.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.1.2. Germany
10.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.1.3. Spain
10.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.1.4. Italy
10.6.1.4.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.4.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.4.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.4.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.1.5. France
10.6.1.5.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.5.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.5.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.5.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
10.6.1.6. Rest of Europe
10.6.1.6.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.6.1.6.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
10.6.1.6.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
10.6.1.6.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)

11. Asia Pacific Anti-Infective Drugs Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.3. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.4. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.5. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.Anti-Infective Drugs Market: By Region, 2022-2032, USD (Million)
11.6.1.Asia Pacific
11.6.1.1. China
11.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.1.2. Japan
11.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.1.3. India
11.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.1.4. Australia
11.6.1.4.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.4.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.4.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.4.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.1.5. South Korea
11.6.1.5.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.5.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.5.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.5.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
11.6.1.6. Rest of Asia Pacific
11.6.1.6.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
11.6.1.6.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
11.6.1.6.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
11.6.1.6.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)

12. Latin America Anti-Infective Drugs Market, 2022-2032, USD (Million)
12.1. Market Overview
12.2. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
12.3. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
12.4. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
12.5. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
12.6.Anti-Infective Drugs Market: By Region, 2022-2032, USD (Million)
12.6.1.Latin America
12.6.1.1. Brazil
12.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
12.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
12.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
12.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
12.6.1.2. Mexico
12.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
12.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
12.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
12.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
12.6.1.3. Rest of Latin America
12.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
12.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
12.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
12.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)

13. Middle East and Africa Anti-Infective Drugs Market, 2022-2032, USD (Million)
13.1. Market Overview
13.2. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
13.3. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
13.4. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
13.5. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
13.6.Anti-Infective Drugs Market: By Region, 2022-2032, USD (Million)
13.6.1.Middle East and Africa
13.6.1.1. GCC
13.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
13.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
13.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
13.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
13.6.1.2. Africa
13.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
13.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
13.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
13.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
13.6.1.3. Rest of Middle East and Africa
13.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2022-2032, USD (Million)
13.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2022-2032, USD (Million)
13.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2022-2032, USD (Million)
13.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2022-2032, USD (Million)

14. Company Profile
14.1. Pfizer Inc.
14.1.1. Company Overview
14.1.2. Financial Performance
14.1.3. Product Portfolio
14.1.4. Strategic Initiatives
14.2. GlaxoSmithKline plc
14.2.1. Company Overview
14.2.2. Financial Performance
14.2.3. Product Portfolio
14.2.4. Strategic Initiatives
14.3. Merck & Co. Inc.
14.3.1. Company Overview
14.3.2. Financial Performance
14.3.3. Product Portfolio
14.3.4. Strategic Initiatives
14.4. Novartis AG
14.4.1. Company Overview
14.4.2. Financial Performance
14.4.3. Product Portfolio
14.4.4. Strategic Initiatives
14.5. Johnson & Johnson
14.5.1. Company Overview
14.5.2. Financial Performance
14.5.3. Product Portfolio
14.5.4. Strategic Initiatives
14.6. Gland Pharma Ltd.
14.6.1. Company Overview
14.6.2. Financial Performance
14.6.3. Product Portfolio
14.6.4. Strategic Initiatives
14.7. Teva Pharmaceutical Industries Ltd.
14.7.1. Company Overview
14.7.2. Financial Performance
14.7.3. Product Portfolio
14.7.4. Strategic Initiatives
14.8. F. Hoffmann-La Roche Ltd.
14.8.1. Company Overview
14.8.2. Financial Performance
14.8.3. Product Portfolio
14.8.4. Strategic Initiatives
14.9. Gilead Sciences, Inc.
14.9.1. Company Overview
14.9.2. Financial Performance
14.9.3. Product Portfolio
14.9.4. Strategic Initiatives
14.10. Abbott
14.10.1. Company Overview
14.10.2. Financial Performance
14.10.3. Product Portfolio
14.10.4. Strategic Initiatives
14.11. Astellas Pharma Inc.
14.11.1. Company Overview
14.11.2. Financial Performance
14.11.3. Product Portfolio
14.11.4. Strategic Initiatives
14.12. Alkem Laboratories
14.12.1. Company Overview
14.12.2. Financial Performance
14.12.3. Product Portfolio
14.12.4. Strategic Initiatives
14.13. AstraZeneca
14.13.1. Company Overview
14.13.2. Financial Performance
14.13.3. Product Portfolio
14.13.4. Strategic Initiatives
14.14. Eli Lilly and Company
14.14.1. Company Overview
14.14.2. Financial Performance
14.14.3. Product Portfolio
14.14.4. Strategic Initiatives
14.15. Takeda Pharmaceutical Company Limited
14.15.1. Company Overview
14.15.2. Financial Performance
14.15.3. Product Portfolio
14.15.4. Strategic Initiatives
14.16. Sanofi
14.16.1. Company Overview
14.16.2. Financial Performance
14.16.3. Product Portfolio
14.16.4. Strategic Initiatives
14.17. Other Notable Players
14.17.1. Company Overview
14.17.2. Financial Performance
14.17.3. Product Portfolio
14.17.4. Strategic Initiatives